VIRGINIA RETIREMENT SYSTEMS ET Al Has $49.07 Million Stake in IDEXX Laboratories, Inc. $IDXX

VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 29.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,808 shares of the company's stock after buying an additional 17,500 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.10% of IDEXX Laboratories worth $49,072,000 at the end of the most recent quarter.Bullish or Bearish? Vetting Animal Health Care StocksSeveral other large investors have also bought and sold shares of the business. Opal Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. Armstrong Advisory Group Inc. grew its stake in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock worth $34,000 after purchasing an additional 19 shares during the period. Ameritas Advisory Services LLC bought a new stake in IDEXX Laboratories in the second quarter valued at about $36,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in IDEXX Laboratories in the second quarter valued at about $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds. Get IDEXX Laboratories alerts:Wall Street Analysts Forecast GrowthSeveral equities analysts have recently issued reports on IDXX shares. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Jefferies Financial Group reissued a "buy" rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Barclays began coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They issued an "overweight" rating and a $850.00 target price for the company. Weiss Ratings reissued a "hold (c+)" rating on shares of IDEXX Laboratories in a research report on Monday. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 29th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average target price of $763.50.Get Our Latest Stock Report on IDEXX LaboratoriesIDEXX Laboratories Stock PerformanceShares of IDXX opened at $682.32 on Wednesday. The firm has a market cap of $54.48 billion, a P/E ratio of 54.11, a PEG ratio of 4.10 and a beta of 1.67. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The firm's 50 day moving average price is $697.50 and its two-hundred day moving average price is $635.11. IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts' consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm's quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year. Insider ActivityIn other news, EVP Nimrata Hunt sold 9,425 shares of the business's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.98% of the stock is owned by corporate insiders. About IDEXX Laboratories (Free Report)IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide. IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.See AlsoFive stocks we like better than IDEXX LaboratoriesDo not delete, read immediatelyThe Crash Has Already Started (Most Just Don’t See It Yet)ALERT: Drop these 5 stocks before January 2026![No Brainer Gold Play]: “Show me a better investment.”INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in IDEXX Laboratories Right Now?Before you consider IDEXX Laboratories, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here